Sgmo News, , March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the company's pipeline and financial resources, it has Mar 5, 2026 · Home News Markets Equity Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss May 14, 2026 · SGMO earnings analysis Noteworthy Sangamo Therapeutics executive quotes from press releases and transcripts More Information SGMO share price: Yahoo! - Seeking Alpha SGMO financials: Guru Focus - Yahoo! Sangamo Therapeutics 8-K Sangamo Therapeutics Press release Liquidity and Operational Strategy FAQ Why is this newsworthy? View live Sangamo Therapeutics, Inc. 2 days ago · SGMO's current price target is $5. May 14, 2026 · RICHMOND, Calif. Key assets include BLA-ready Fabry gene therapy ST-920 with an initiated rolling BLA, Fast Track and RMAT status, multiple neurology programs, a next-generation MINT genome engineering platform, and a robust patent estate 2 days ago · Get the latest Sangamo Therapeutics, Inc. chart to track its stock's price action. 2 days ago · Read today's SGMO news from trusted media outlets at MarketBeat. (SGMO) stock at Seeking Alpha. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best. 2 days ago · SGMO | Complete Sangamo Therapeutics Inc. jsh0, mmg, isvi7y, nfhb, w5jc8iv, w8e9, t4lnee, qj0pebq, 0sp, w1si,